Abstract
Acadia Healthcare will release its quarterly results on November 04, 2026 Post-Mkt, with consensus looking for modest year-over-year revenue growth and softer earnings as the company balances facility ramp-up, payer-rate trends, and expense normalization.
Market Forecast
Consensus points to revenue of 877.79 million US dollars for the current quarter, up 3.79% year over year, with estimated adjusted EPS at 0.46, down 30.93% year over year, and EBIT at 104.22 million US dollars, down 16.84% year over year. Margin forecasts were not disclosed, but investors will focus on the interaction between rate increases and cost normalization to gauge profitability continuity relative to recent quarters.
The company’s business mix remains skewed toward payer-funded services, and market commentary highlights stable to modestly improving pricing alongside healthy occupancy as key supports for near-term revenue. Medicaid-funded care remains the most prominent segment by scale, with last quarter revenue of 540.23 million US dollars; while segment-level year-over-year growth was not disclosed, recent commentary indicates low- to mid-single-digit rate increases and continued occupancy ramp at new and recently expanded facilities.
Last Quarter Review
Acadia Healthcare reported revenue of 865.84 million US dollars, a gross profit margin of 41.76%, GAAP net profit attributable to shareholders of 10.93 million US dollars, a net profit margin of 1.26%, and adjusted EPS of 0.38 (down 54.22% year over year), while revenue decreased 0.39% year over year and net profit improved sequentially with a quarter-on-quarter increase of 166.21%.
A notable feature of the quarter was the increased professional and general liability reserves, which dampened profitability despite steady demand and healthy payer-rate execution, setting a tougher year-over-year comparison for earnings quality. By segment (payer mix), Medicaid generated 540.23 million US dollars, Commercial contributed 185.80 million US dollars, Medicare contributed 122.29 million US dollars, Self-pay accounted for 9.51 million US dollars, and Other accounted for 8.02 million US dollars; total revenue declined 0.39% year over year on these volumes and mix.
Current Quarter Outlook
Main business performance and margin pathway
The core franchise continues to revolve around payer-funded behavioral health services with a scaled, multi-payer mix that has shown resilience through varying cost cycles. The near-term operating question remains whether facility-level occupancy gains and low- to mid-single-digit contract rate increases can offset wage normalization, insurance-related accruals, and new-facility startup costs. Consensus revenue growth of 3.79% year over year suggests the demand environment remains constructive and that rate-setting outcomes have been sufficient to produce modest top-line expansion even as earnings absorb cost and reserve headwinds.
Gross profit dynamics are anchored by throughput and payer mix; with last quarter’s gross margin at 41.76%, the baseline suggests an opportunity to sustain margins near the low-40s when census and case acuity hold, though reported profitability is sensitive to any incremental accruals or reserve updates. The net margin at 1.26% highlights how even modest changes in non-operating items, reserves, or discrete costs can materially influence bottom-line conversion in a given quarter, which is reflected in the forecasted year-over-year declines for EBIT and EPS. Against that backdrop, investors will pay particular attention to same-facility trends, labor scheduling efficiency, and payor authorizations, which together influence service mix and length-of-stay, and therefore margin continuity, more than broad industry factors in the near term.
Largest growth opportunity and its scale
The largest revenue opportunity by sheer scale remains Medicaid-funded services, which delivered 540.23 million US dollars last quarter and accounts for the majority of the payer mix. New and expanded facilities are ramping occupancy faster than in recent periods, aided by improved licensing throughput and stronger managed care coordination, which supports Medicaid census and mitigates startup losses more quickly. While segment-level year-over-year growth rates were not disclosed, market commentary pointing to low- to mid-single-digit rate improvements suggests the revenue line can compound provided unit growth and occupancy continue tracking to plans.
The Commercial segment at 185.80 million US dollars is the secondary pillar and offers incremental pricing leverage, although utilization and authorization patterns can swing intra-quarter outcomes. Medicare at 122.29 million US dollars remains a meaningful contributor and can add stability, with the trade-off that pricing is more programmatic and less flexible than Commercial arrangements. Across these segments, the common denominator for accelerating revenue and earnings is the pace of occupancy ramp in newly opened facilities and the speed at which those assets cross the breakeven threshold and then scale margins toward the system average.
Key stock-price drivers this quarter
The first determinant for this print is revenue-conversion quality versus mix: investors will parse admissions growth, average length-of-stay, and payer approvals to assess whether top-line strength is being driven by sustainable utilization rather than transient case mix. The second determinant is cost discipline, especially staffing utilization and overtime containment, as labor remains the principal input to service delivery, and even modest deviations can affect gross margin and earnings power. The third determinant is any update to insurance and liability accruals; the prior reserve increase raised scrutiny on the cadence and sufficiency of accruals, and a quieter quarter on that front would likely be interpreted as a step toward earnings normalization.
Consensus embeds a 16.84% year-over-year decline in EBIT to 104.22 million US dollars and a 30.93% decline in adjusted EPS to 0.46, suggesting that while volumes and rates underpin revenue growth, the market still assumes conservative margin capture. If facility ramp continues to run ahead of startup assumptions and payer relationships support consistent approvals, the balance of probabilities would favor stabilization in profitability metrics as the calendar year closes. Conversely, any new expense items, reserve adjustments, or staffing pressures could keep conversion muted despite the improving revenue base.
Analyst Opinions
The balance of recent opinions is predominantly bullish, with multiple Buy/Outperform ratings and an average stance that can be summarized as overweight. One widely referenced view maintains a Buy rating and a 40.00 US dollars price target, noting steady operational execution and improved accountability as drivers of accelerating occupancy ramps and more predictable startup curves at new facilities. Additional positive ratings with targets around 31.00 US dollars emphasize the same execution thread, pointing to strengthened licensing throughput, improved payer contracting, and occupancy trajectories that are beating earlier startup expectations.
A separate update lowered a rating to Outperform from a stronger designation but kept a constructive stance, underscoring that the change reflected calibration of near-term risk-reward rather than a shift in structural outlook. Recent commentary also highlighted a payer environment that continues to stabilize, with low- to mid-single-digit rate increases and generally supportive managed care relationships, important for revenue visibility in the coming quarters. At the same time, analysts continue to monitor the company’s liability-reserve profile after the prior quarter’s 28.60 million US dollars increase; most constructive views assume a less volatile path for that line item, which would allow the underlying operating trend to come through more clearly in EPS and cash flow.
Aggregating these perspectives, the ratio of bullish to bearish views skews heavily positive, with a clear majority reiterating Buy or Outperform ratings and price targets that frame upside contingent on execution against the facility expansion plan and steady payer dynamics. The central bullish case rests on three points: sustained demand and census growth supporting mid-single-digit top-line expansion, disciplined cost management that gradually restores margin capture as staffing stabilizes, and a maturing new-build pipeline that reduces startup drag while increasing system scale. Under this framework, the current consensus for 877.79 million US dollars in revenue and 0.46 adjusted EPS is treated as a conservative checkpoint that the company can potentially exceed if mix and costs trend favorably and if reserve adjustments are benign.
From a near-term trading perspective, investors will likely reward evidence that revenue growth is translating into consistent gross margin performance near the low-40s and that EBIT conversion is stabilizing after recent reserve noise. Stronger occupancy ramps and cleaner expense prints could catalyze positive estimate revisions, while any surprise in accruals or wage lines could lead to cautious resets. Overall, the majority institutional view into November 2026 is that the setup is constructive for revenue and cautiously optimistic for earnings normalization, with facility ramp and payer execution as the primary levers for upside over the next several quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments